Tcg Crossover Gp Ii, Llc Acquires 1,093 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc purchased 1,093 shares of the stock in a transaction on Thursday, February 12th. The shares were purchased at an average cost of $23.86 per share, with a total value of $26,078.98. Following the transaction, the insider owned 651,114 shares in the company, valued at $15,535,580.04. This trade represents a 0.17% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc purchased 17,763 shares of Surrozen stock. The stock was acquired at an average price of $23.57 per share, for a total transaction of $418,673.91.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc acquired 4,355 shares of Surrozen stock. The stock was acquired at an average cost of $21.94 per share, for a total transaction of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc purchased 731 shares of Surrozen stock. The stock was acquired at an average cost of $21.38 per share, for a total transaction of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc bought 4,271 shares of Surrozen stock. The shares were bought at an average cost of $21.39 per share, for a total transaction of $91,356.69.

Surrozen Price Performance

Shares of NASDAQ SRZN opened at $24.48 on Friday. The stock has a market capitalization of $209.79 million, a price-to-earnings ratio of -1.10 and a beta of 0.58. The firm’s 50 day simple moving average is $21.59 and its 200-day simple moving average is $15.80. Surrozen, Inc. has a 12 month low of $5.90 and a 12 month high of $25.84.

Institutional Investors Weigh In On Surrozen

Hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. boosted its stake in shares of Surrozen by 50.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock valued at $34,000 after buying an additional 500 shares during the period. Citadel Advisors LLC raised its holdings in Surrozen by 32.8% in the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after acquiring an additional 3,424 shares in the last quarter. Geode Capital Management LLC lifted its stake in Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after acquiring an additional 5,702 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Surrozen by 53.6% during the 4th quarter. Renaissance Technologies LLC now owns 22,626 shares of the company’s stock worth $511,000 after acquiring an additional 7,900 shares in the last quarter. Finally, Acuta Capital Partners LLC increased its position in shares of Surrozen by 5.0% in the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after purchasing an additional 8,415 shares during the last quarter. Institutional investors and hedge funds own 66.57% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on SRZN. Lifesci Capital upgraded shares of Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. Wall Street Zen upgraded Surrozen to a “sell” rating in a report on Friday, November 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.